Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. (NASDAQ: ASRT) is a specialty pharmaceutical company headquartered in Lake Forest, Illinois. The company is dedicated to advancing patient care through the commercialization of differentiated products in the areas of neurology, orphan, and specialty medicines. Assertio's portfolio includes three FDA-approved products:
- Gralise: Extended-release tablets for the management of postherpetic neuralgia.
- CAMBIA: A solution for the acute treatment of migraine attacks with or without aura in adults.
- Zipsor: Liquid-filled capsules for the relief of mild to moderate pain.
In August 2023, Assertio completed the acquisition of Spectrum Pharmaceuticals, Inc., bringing the innovative ROLVEDON™ to its portfolio. This addition is poised to diversify Assertio’s revenue base and enhance its commercial capabilities. Despite some challenges, including competition from generic drugs, Assertio remains committed to leveraging its digital non-personal sales model to drive growth and efficiency.
Financially, Assertio reported substantial cash flow from operations and maintained a robust cash position. The company continues to explore strategic acquisitions and licensing opportunities to expand its portfolio and drive long-term growth. Recent leadership changes and the appointment of experienced executives underscore Assertio’s commitment to optimizing its commercial strategies and maintaining financial stability.
Assertio’s forward-looking strategy involves not only enhancing its current product offerings but also advocating for patient access to medications through legislative efforts. The company’s non-personal promotional model and strategic acquisitions ensure its adaptability in a competitive market. For more detailed financial data and corporate updates, visit Assertio's investor relations website.
Assertio Holdings, Inc. (Nasdaq: ASRT) announced the release date for its first quarter 2023 financial results, which is set for May 9, 2023, after market close. Following this release, management will conduct a live webcast earnings conference call at 4:30 p.m. Eastern Time. Investors can access the call via the company's investor relations website. A replay will be available approximately two hours after the call concludes.
Assertio is a specialty pharmaceutical company focused on offering differentiated products to patients. It utilizes a non-personal promotional model and is actively building its commercial portfolio through existing products and potential acquisitions or licensing of approved products.
Assertio has announced a definitive agreement to acquire Spectrum Pharmaceuticals in an all-stock and contingent value rights transaction. Spectrum stockholders will receive 0.1783 shares of Assertio for each Spectrum share, representing an upfront value of $1.14 per share and a premium of 65% to Spectrum's latest closing price. Total potential consideration can reach $1.34 per share, with a premium of 94%. The transaction is expected to close in Q3 2023, resulting in Assertio stockholders owning approximately 65% and Spectrum stockholders approximately 35% of the combined entity. This acquisition is anticipated to be accretive to Assertio's adjusted EPS and operating cash flow in 2024, leveraging Spectrum's commercial capabilities and the ROLVEDON product to enhance market access.
Assertio Holdings, Inc. (Nasdaq: ASRT) has announced a $100,000 educational grant to the Lennox-Gastaut Syndrome (LGS) Foundation to support the launch of their 'About LGS Treatments Kits' aimed at assisting families affected by LGS. This initiative aims to provide crucial information regarding seizure treatments and management options for LGS patients aged two years and older, who are treated with SYMPAZAN (clobazam) oral film. SYMPAZAN is the only FDA-approved oral film formulation for adjunctive treatment of seizures linked to LGS. Assertio's initiative reflects its commitment to enhancing awareness and education around LGS, as emphasized by the company's CEO, Dan Peisert.
FAQ
What is the current stock price of Assertio Holdings (ASRT)?
What is the market cap of Assertio Holdings (ASRT)?
What products does Assertio Holdings, Inc. offer?
What is the significance of Assertio’s acquisition of Spectrum Pharmaceuticals?
How does Assertio promote its products?
What are some of Assertio's recent financial highlights?
Who are some of the key leadership figures at Assertio?
What challenges does Assertio face with generic competition?
What is Assertio’s strategy for long-term growth?
How can investors access information about Assertio?
What role does Assertio play in legislative advocacy?
What is Assertio’s approach to sales and marketing?
